New approaches to modulating idiopathic pulmonary fibrosis

Current Allergy and Asthma Reports

Volumn 13, Issue 6, 2013, Pages 607-612

  Gomer, Richard H ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Clinical trials; Fibrocyte; Fibrosing; Idiopathic pulmonary fibrosis; Lung; Macrophage; Modulation; Salt intake; Therapeutics; Treatment

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; AZATHIOPRINE; BOSENTAN; CARBON MONOXIDE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; EVEROLIMUS; GAMMA INTERFERON; HISTAMINE H2 RECEPTOR ANTAGONIST; IMATINIB; LIVER ENZYME; NINTEDANIB; PIRFENIDONE; PLACEBO; PREDNISONE; PROTON PUMP INHIBITOR; SERUM AMYLOID P; SILDENAFIL; WARFARIN;

ARTICLE; CHINA; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG APPROVAL; DRUG FATALITY; EUROPEAN UNION; FIBROSING ALVEOLITIS; GASTROINTESTINAL REFLUX; HUMAN; INDIA; JAPAN; LUNG FUNCTION; NAUSEA; NONHUMAN; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; RASH; SINGLE DRUG DOSE; SODIUM RESTRICTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; GASTROINTESTINAL TRACT; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MACROPHAGES; SERUM AMYLOID P-COMPONENT;

EID: 84890566394     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-013-0377-5     Document Type: Article

References (65)

1. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007;176(3):277-84.
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824. Latest official guidelines for diagnosis and treatment of IPF.
3. • Wells AU. Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev. 2013;22(128):158-62. Points out difficulties with the diagnosis.
4. Schmidt M, Sun G, Stacey M, Mori L, Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol. 2003;171:380-9.
5. • Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723-37. Shows the presence of peribronchiolar fibrosis in asthma.
6. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med. 2006;173(7):781-92.
7. • Ploeger DT, Hosper NA, Schipper M, Koerts JA, de Rond S, Bank RA. Cell plasticity in wound healing: paracrine factors of M1/ M2 polarized macrophages influence the phenotypical state of dermal fibroblasts. Cell Commun Signal. 2013;11(1):29. Shows that signals from human M2a macrophages stimulate proliferation of human (dermal) fibroblasts.
8. Murray LA, Rosada R, Moreira AP, Joshi A, Kramer MS, Hesson DP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One. 2010;5(3):e9683.
9. Duffield JS, Lupher M, Thannickal VJ, Wynn TA. Host responses in tissue repair and fibrosis. Annu Rev Pathol. 2013;8:241-76.
10. Wight TN, Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J Physiol Gastrointest Liver Physiol. 2011;301(6):G950-5.
11. Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A. 2011;108(52):E1475-83.
12. Bucala R, Spiegel L, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994;1:71-81.
13. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep. 2006;8(2):145-50.
14. Herzog EL, Bucala R. Fibrocytes in health and disease. Exp Hematol. 2010;38(7):548-56.
15. Yang L, Scott P, Giuffre J, Shankowsky H, Ghahary A, Tredget E. Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab Invest. 2002;82(9):1183-92.
16. Wang JF, Jiao H, Stewart TL, Shankowsky HA, Scott PG, Tredget EE. Fibrocytes from burn patients regulate the activities of fibroblasts. Wound Repair Regen. 2007;15(1):113-21.
17. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2009;2(2):103-21.
18. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, Smith AM, et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog. 2009;5(4):e1000371.
19. Hedrich CM, Bream JH. Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol Res. 2010;47(1-3):185-206.
20. Sode BF, Dahl M, Nielsen SF, Nordestgaard BG. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med. 2010;181(10):1085-92.
21. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186(1):88-95.
22. Peikert T, Daniels CE, Beebe TJ, Meyer KC, Ryu JH. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med. 2008;102(9):1342-8.
23. Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968-77.
24. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181(6):604-10.
25. Malouf MA, Hopkins P, Snell G, Glanville AR. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology. 2011;16(5):776-83.
26. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158(9):641-9.
27. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136-42.
28. Raghu G. Idiopathic pulmonary fibrosis: increased survival with "gastroesophageal reflux therapy": fact or fallacy? Am J Respir Crit Care Med. 2011;184(12):1330-2.
29. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006;129(3):794-800.
30. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390-4.
31. He FJ, MacGregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Hum Hypertens. 2009;23(6):363-84.
32. Yuan BX, Leenen FH. Dietary sodium intake and left ventricular hypertrophy in normotensive rats. Am J Physiol. 1991;261(5 Pt 2):H1397-401.
33. Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation. 1998;98(23):2621-8.
34. Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567.
35. He FJ, Burnier M, Macgregor GA. Nutrition in cardiovascular disease: salt in hypertension and heart failure. Eur Heart J. 2011;32(24):3073-80.
36. Cox N, Pilling D, Gomer RH. NaCl potentiates human fibrocyte differentiation. PLoS One. 2012;7(9):e45674.
37. Singh TP. Clinical use of sildenafil in pulmonary artery hypertension. Expert Rev Respir Med. 2010;4(1):13-9.
38. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620-8.
39. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, et al. Sildenafil Preserves Exercise Capacity in Patients With Idiopathic Pulmonary Fibrosis and Right-sided Ventricular Dysfunction. Chest. 2013;143(6):1699-708. Describes the subset of IPF patients for whom sildenafil may be useful.
40. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995;125(6):779-85.
41. Gan Y, Herzog EL, Gomer RH. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag. 2011;7:39-47.
42. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-9.
43. Raghu G, Thickett DR. Pirfenidone for IPF: pro/con debate; the 'con' viewpoint. Thorax. 2013.
44. Jiang C, Huang H, Liu J, Wang Y, Lu Z, Xu Z. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS One. 2012;7(10):e47024.
45. Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol. 2003;17(10):5537-46.
46. Pilling D, Roife D, Wang M, Ronkainen SD, Crawford JR, Travis EL, et al. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol. 2007;179(6):4035-44.
47. Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, Crawford JR, et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A. 2006;103(48):18284-9.
48. Castaño AP, Lin S-L, Surowy T, Nowlin BT, Turlapati SA, Patel T, et al. Serum Amyloid P Inhibits Fibrosis Through FcγR-Dependent Monocyte-Macrophage Regulation in Vivo. Sci Transl Med. 2009;1(5):5ra13.
49. Zhang W, Wu J, Qiao B, Xu W, Xiong S. Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease. PLoS One. 2011;6(7):e22659.
50. Moreira AP, Cavassani KA, Hullinger R, Rosada RS, Fong DJ, Murray L, et al. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J Allergy Clin Immunol. 2010;4:712-21.
51. Murray LA, Kramer MS, Hesson DP, Watkins BA, Fey EG, Argentieri RL, et al. Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. Fibrogenesis Tissue Repair. 2010;3:11.
52. Ji Z, Ke ZJ, Geng JG. SAP suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. Immunol Cell Biol. 2011.
53. Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, Peng X, et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol. 2011;43(1):154-62.
54. Naik-Mathuria B, Pilling D, Crawford JR, Gay AN, Smith CW, Gomer RH, et al. Serum amyloid P inhibits dermal wound healing. Wound Repair Regen. 2008;16(2):266-73.
55. Nelson S, Tennent G, Sethi D, Gower P, Ballardie F, Amatayakul-Chantler S, et al. Serum amyloid P component in chronic renal failure and dialysis. Clin Chim Acta. 1991;200(2-3):191-9.
56. Naylor MC, Lazar DA, Zamora IJ, Mushin OP, Yu L, Brissett AE, et al. Increased in vitro differentiation of fibrocytes from keloid patients is inhibited by serum amyloid P. Wound Repair Regen. 2012;20(3):277-83.
57. Bharadwaj D, Mold C, Markham E, Du Clos TW. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol. 2001;166(11):6735-41.
58. Bijl M, Horst G, Bijzet J, Bootsma H, Limburg PC, Kallenberg CG. Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. Arthritis Rheum. 2003;48(1):248-54.
59. Familian A, Zwart B, Huisman HG, Rensink I, Roem D, Hordijk PL, et al. Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol. 2001;167(2):647-54.
60. Maharjan AS, Roife D, Brazill D, Gomer RH. Serum amyloid P inhibits granulocyte adhesion. Fibrogenesis Tissue Repair. 2013;6(1):2.
61. Dillingh MR, van den Blink B, Moerland M, van Dongen MG, Levi M, Kleinjan A, et al. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther. 2013.
62. Van Den Blink B, Burggraaf J, Morrison LD, Ginns LC, Wijsenbeek MS, Moerland M, et al. A Phase I Study Of PRM-151 In Patients With Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2013;187:A5705.
63. Adamali HI, Maher TM. Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther. 2012;6:261-72.
64. Rafii R, Juarez MM, Albertson TE, Chan AL. A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis. 2013;5(1):48-73.
65. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079-87.